• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.530 -0.140 (-8.38%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,203,004
Open 1.660
Bid (Size) 1.500 (700)
Ask (Size) 1.570 (300)
Prev. Close 1.670
Today's Range 1.470 - 1.700
52wk Range 1.100 - 2.680
Shares Outstanding 144,474,452
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lexicon Pharmaceuticals Sets Sights on Heart Trial Results, Diabetes Drug Resubmission in 2027 ↗
Today 16:12 EST
Lexicon Pharmaceuticals (NASDAQ:LXRX) expects first-quarter results next year from a late-stage study of sotagliflozin in hypertrophic cardiomyopathy, while preparing to resubmit the drug for type 1... 
Via MarketBeat
News headline image
Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
November 11, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

52-Week Range 42.9% below 52-week high
1.530
1.1052W Low 2.6852W High
1 Week 16.8% below 1-week high
1.671W Low 1.841W High

Lexicon Pharmaceuticals, Inc. - Common Stock (LXRX) traded between $1.10 and $2.68 over the past 52 weeks and last traded at $1.53, 42.9% below its 52-week high. Over the past week it ranged between $1.67 and $1.84.

Past 12 Months
-14.5%
-3.2%
-29.8%
-31.4%
+34.2%
+5.5%
1W -$0.26
1M -$0.05
3M -$0.65
6M -$0.70
YTD +$0.39
1Y +$0.08

LXRX was +5.5% over the past year, -31.4% over six months, +34.2% year to date, -14.5% in the last week.

12 Months vs Market
LXRX
+5.5%
DIA
+4.2%
SPY
+4.1%
QQQ
+1.4%
IWM
+9.9%

Over the past 12 months LXRX returned +5.5% versus DIA (Dow) +4.2%, SPY (S&P 500) +4.1%, QQQ (Nasdaq 100) +1.4% and IWM (Russell 2000) +9.9%.

Volume & Liquidity 1.64× 3-mo avg
Today 4,203,004 3-mo avg 2.6M
1W
1.9M
1M
2.1M
3M
2.6M
6M
2.9M
YTD
2.9M
1Y
2.7M

LXRX most recently traded 4,203,004 shares against a 3-month average daily volume of 2.6M.

More News

Read More
News headline image
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
November 09, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call ↗
November 06, 2026
Via MarketBeat
Topics Earnings
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q3 2026 Beat Rests on Novo Milestone as SONATA-HCM and ZYNQUISTA Catalysts Loom ↗
November 05, 2026
Via Chartmill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses Estimates ↗
August 06, 2026
Via Chartmill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally ↗
July 08, 2026
Via Chartmill
News headline image
Lexicon (LXRX) Q3 2026 Earnings Call Transcript ↗
November 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
November 05, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
October 29, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
October 23, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
October 21, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today ↗
September 28, 2026
Via The Motley Fool
News headline image
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data ↗
September 20, 2026
Via MarketBeat
News headline image
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
September 01, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
August 31, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
August 24, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon (LXRX) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
News headline image
Lexicon Pharmaceuticals Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics Earnings
News headline image
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 06, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
July 27, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗
June 11, 2026
Via The Motley Fool
News headline image
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
June 03, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
June 01, 2026
Via The Motley Fool

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?
Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market
What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?
The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.530
When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 221.05M
How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?
Lexicon Pharmaceuticals, Inc. - Common Stock has 221M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap